Premium
Anti‐Cancer Therapies of 21st Century: Novel Approach to Treat Human Cancers Using Cold Atmospheric Plasma
Author(s) -
Ratovitski Edward A.,
Cheng Xiaoqian,
Yan Dayun,
Sherman Jonathan H.,
Canady Jerome,
Trink Barry,
Keidar Michael
Publication year - 2014
Publication title -
plasma processes and polymers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.644
H-Index - 74
eISSN - 1612-8869
pISSN - 1612-8850
DOI - 10.1002/ppap.201400071
Subject(s) - apoptosis , reactive oxygen species , cancer cell , cancer , cancer research , programmed cell death , reactive nitrogen species , cell , atmospheric pressure plasma , cell cycle checkpoint , cell cycle , chemistry , microbiology and biotechnology , biology , medicine , biochemistry , plasma , physics , quantum mechanics
Cold atmospheric plasma (CAP) has just recently been showing promising anti‐cancer activities supported by ability to induce cell death via apoptosis and cell cycle arrest leading to tumor cell destruction in vitro, and in vivo. Several studies showed the ability of CAP‐activated media to modulate the tumor cell environment a link between the generation of reactive oxygen species/reactive nitrogen species and cancer cell death following CAP treatment. Targeting cancer cells through ROS‐mediated mechanisms has become an attractive strategy for effective and selective cancer treatment by exploiting the aberrant redox characteristics of cancer cells. These effects support the potential direct (CAP) and indirect (CAP‐activated media) applications for adjuvant anti‐cancer therapeutics, in a combination with the chemo‐, radio‐, and nano‐therapies.